News headlines about Ampliphi Biosciences Corp (NYSE:APHB) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ampliphi Biosciences Corp earned a news impact score of 0.15 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.8217707022966 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Ampliphi Biosciences Corp (APHB) traded down 1.94% during mid-day trading on Tuesday, reaching $0.76. The company had a trading volume of 40,531 shares. The stock’s market capitalization is $5.04 million. Ampliphi Biosciences Corp has a 52-week low of $0.67 and a 52-week high of $19.90. The company’s 50-day moving average is $1.97 and its 200 day moving average is $1.04.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Ampliphi Biosciences Corp (APHB) Stock Price” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at

Ampliphi Biosciences Corp Company Profile

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.